FDA Approves Selpercatinib; Pralsetinib May Soon Follow

Abstract The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non–small cell lung cancer (NSCLC) and certain types of thyroid cancer. Another RET inhibitor, pralsetinib, has been submitted for approval to treat NSCLC. Both drugs have shown effectiveness in treating brain metastases.